The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

“Call-on Congress” convenes advocates, legislators, health officials to rally for better CRC screening rates and outcomes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Fight Colorectal Cancer hosted an advocacy event on the National Mall March 16, “Call-on Congress,” to discuss ways to reduce colorectal cancer incidence, improve treatment, and mitigate health disparities. The event included a flag installation on the Mall to honor those affected by CRC. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account